

**Annual General Meeting of Shareholders
of
HLS THERAPEUTICS INC.
(the “Company”)**

**June 17, 2022
REPORT OF VOTING RESULTS**

Pursuant to Section 11.3 of
National Instrument 51-102 – *Continuous Disclosure Obligations* (“**NI 51-102**”)

In accordance with section 11.3 of NI 51-102 and following the annual general meeting of shareholders of the Company held on June 17, 2022 (the “**Meeting**”), we hereby advise of the following voting results as tabulated.

Total common shares issued and outstanding at record date (May 14, 2021)	32,467,724
Total shares represented at the Meeting in person and by proxy	23,394,920
Percentage of total shares represented at the Meeting	72.06%

Election of Directors

The election of directors was conducted by ballot. Each of the ten nominees in the Company’s management information circular dated May 13, 2022 was elected to serve until the end of the next annual meeting of shareholders or until his or her successor is duly elected or appointed. The percentage of votes cast “for” or “withheld” from the vote are set forth below opposite the name of each elected director based on proxies and votes received at the Meeting.

Name of Nominee	Votes Cast FOR	% of Vote Cast FOR	Votes WITHHELD	% of Votes WITHHELD
Gilbert Godin	20,753,293	99.75	51,396	0.25
Greg Gubitz	20,712,831	99.75	51,432	0.25
J. Spencer Lanthier	20,662,746	99.51	101,517	0.49
Yvon Bastien	19,646,377	94.62	1,117,886	5.38
Rodney Hill	20,518,531	98.82	245,732	1.18
Don DeGolyer	17,454,248	84.09	3,310,015	15.94
Laura Brege	19,567,322	94.24	1,196,941	5.76
John Welborn	20,524,460	98.85	239,803	1.15
Norma Beauchamp	19,634,591	94.56	1,129,672	5.44

Re-Appointment of Auditor

An ordinary resolution to re-appoint Ernst & Young LLP to serve as the independent auditor of the Company and authorizing the directors of the Company to fix the auditor’s remuneration was approved by ballot. Based on proxies and votes received at the Meeting, 23,201,466 votes 99.18% were cast “for” and 191,954 votes 0.82% were withheld.